The U.S. Food and Drug Administration approved the design of IceCure Medical’s ChoICE post-marketing study for its FDA-cleared ProSense cryoablation system in low-risk breast cancer, a surveillance requirement tied to the agency’s October 2025 marketing authorization. The study is expected to enroll about 400 patients across 30 U.S. sites, and participating facilities may bill procedures using an existing CPT Category III reimbursement code.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603110830PR_NEWS_USPR_____LN07767) on March 11, 2026, and is solely responsible for the information contained therein.